A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|21|3797-3804

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.21, 2013-11, pp. : 3797-3804

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 539-546

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 3, 2018-02 ,pp. : 365-373

John Wiley & Sons Inc

Access to resources Recommend Favorite

Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced‐stage follicular lymphoma: A cost‐effectiveness analysis

By  

CANCER, Vol. 121, Iss. 15, 2015-08 ,pp. : 2637-2645

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

By  

CANCER, Vol. 124, Iss. 4, 2018-02 ,pp. : 688-697

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Trial of Weekly Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 224-228

Karger

Access to resources Recommend Favorite